Brazil ends 100% dependence on blood product imports worth US$400m
This article was originally published in Clinica
Executive Summary
Brazil’s state-owned blood products and biotechnology firm Hemobr�s has begun to operate the first unit of a state-of-the-art 14-facility blood storage and processing complex. The news marks the beginning of the end of the country’s “100% dependence” on imported haemoderivatives, to become self-sufficient by 2014.